Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

16.02.2023 - - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts ...

Related Keywords

United States ,Boston ,Massachusetts ,Philadelphia ,Pennsylvania ,America ,Inozyme Pharma ,Matt Pera ,Michaela Levine ,Kurt Gunter ,Axel Bolte ,Mark Kiel ,Wilko Spiering ,Stefan Riley ,Michael Levine ,Division Of Internal Medicine ,University Medical Center Utrecht Of ,Linkedin ,Twitter ,Inozyme Pharma Inc ,Division Of Endocrinology ,Bone Health ,Department Of Vascular Medicine ,Nasdaq ,Exchange Commission ,Children Hospital Of Philadelphia Research Institute ,International Number ,Corporate Communications ,Facebook ,Professor Emeritus ,Chief Emeritus ,Philadelphia Research ,Drug Antibody ,Analyst Event ,Conference Call ,Philadelphia Research Institute ,Associate Professor ,Internal Medicine ,Vascular Medicine ,University Medical Center ,Utrecht University ,Chief Science Officer ,Dial In Number ,North America ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,